Patients with ANCA-associated vasculitis receiving low glucocorticoid doses as per the PEXIVAS trial faced an increased risk ...

The U.S. Food and Drug Administration gave SC291, a CD19-directed allogeneic CAR T cell therapy developed using Sana's hypoimmune platform, fast track designation, a process designed to facilitate the ...

Sana Biotechnology results from the phase 1 study using SC291 for the treatment of patients with SLE are expected in 2025.

The U.S Food and Drug Administration (FDA) granted Fast Track Designation to Sana Biotechnology’s SC291 for ...

1 Musculoskeletal Collaboration, School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK 2 School of Immunity and Infection, University of Birmingham, Birmingham, UK Objectives To ...

The final criteria and their weights were as follows: bloody nasal discharge, nasal crusting or sino-nasal congestion (+3); cartilaginous involvement (+2); conductive or sensorineural hearing loss (+1 ...

SC291, a hypoimmune-modified CD19-directed allogeneic CAR T therapy, is being evaluated in Sana’s GLEAM trial in patients with B-cell mediated autoimmune diseases including lupus nephritis, extrarenal ...

After hours: December 9 at 6:57:41 PM EST Loading Chart for SANA ...

Fast Track designation is designed to expedite clinical development and regulatory review timelinesEnrolling patients in the GLEAM trial for ...

The main features are nonspecific: fever, myalgias and malaise. Although these patients have positive antineutrophil cytoplasmic antibodies and accelerated ESR, the diagnosis is established by ...

Autoantibodies such as antinuclear antibody (ANA), antineutrophil cytoplasmic antibody (ANCA) and anticardiolipin antibodies (ACL) are not usually found in the sera of patients with Behçet's ...